|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 555 11th STREET, NW |
Address2 | Suite #300 |
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 288670-12
|
||||||||
|
6. House ID# 371000000
|
TYPE OF REPORT | 8. Year | 2019 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Keysha Brooks-Coley |
Date | 1/21/2020 10:14:22 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
FY 2020 federal appropriations for cancer research and prevention funding at the NIH, NCI and CDC; policy issues and funding related to the CDCs and FDAs tobacco work; issues and funding related to non-communicable diseases; funding for cancer programs within the CDMRP; issues related to global health funding for cervical cancer screening & treatment and HPV vaccination; and issues related to highway authorization and appropriations.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Centers For Disease Control & Prevention (CDC), State - Dept of (DOS), Food & Drug Administration (FDA), Natl Institutes of Health (NIH), Veterans Affairs - Dept of (VA), U.S. Agency for International Development (USAID), Energy - Dept of, Defense - Dept of (DOD), Transportation - Dept of (DOT)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Caroline |
Powers |
|
|
|
Gregg |
Haifley |
|
|
|
Denys |
Symonette |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Rosalie |
Abbott |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues related to implementation of legislative or regulatory changes to Medicare and Medicaid, including:
HR 1948, Lymphedema Treatment Act;
HR 6808, Patient Navigation Assistance Act;
HR 1570 and S. 668, the Removing Barriers to Colorectal Cancer Screening Act, and regulatory issues related to the Medicare coinsurance issue in these bills;
S.2218 and H.R 4821, the Covering Our FAS Allies (COFA) Act & issues related to Medicaid coverage for Compacts of Free Association (COFA) migrants;
CMS-issued regulations pertaining to Medicare Part B reimbursement - the CY2020 Medicare Physician Fee Schedule;
HR 913, The CLINICAL TREATMENT Act, Medicaid covering routine care costs for beneficiaries who participate in an approved clinical trial;
Issues related to potential Administration guidance relating to giving states the option to block grant their Medicaid program;
Issues related to Puerto Ricos Medicaid program, including H.R. 3631, Territories Health Care Improvement Act;
H.R. 3, the Lower Drug Prices Now Act - legislation for lowering prescription drug costs, lowering out of pocket expenses for Medicare beneficiaries, and placing a cap on Medicare Part D;
S. 2543, the Prescription Drug Pricing Reduction Act of 2019 - legislation for lowering prescription drug costs, lowering out of pocket costs for Medicare beneficiaries, and placing a cap on Medicare Part D;
Issues related to Medicaid Non-Emergency Medical Transportation; and
S. 2911 - Seniors Prescription Drug Relief Act of 2019, would allow Medicare beneficiaries who reach an out of pocket cap to spread their payments over the course of the entire year.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Caroline |
Powers |
|
|
|
Gregg |
Haifley |
|
|
|
Denys |
Symonette |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Rosalie |
Abbott |
|
|
|
Stephanie |
Krenrich |
|
|
|
Phylicia L. |
Woods |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOB
16. Specific lobbying issues
Issues relating to smoking cessation, age of sale of tobacco products, tobacco taxes, graphic warning labels, product regulation, and smoke-free environments, including:
Implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the FDA deeming regulation;
Issues relating to FDA regulation of electronic cigarettes and cigars;
S. 655 and H.R.1498, Stopping Appealing Flavors in E-Cigarettes for Kids Act;
S. 1048 and H.R. 2111, Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction Act;
H.R.1854 & S.9, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act;
H.R. 2084, the Stopping Consumption of Tobacco by Teens Act of 2019;
H.R. 2339 and S. 3174, Reversing the Youth Tobacco Epidemic Act;
S. 1258 and H.R. 2411, Tobacco to 21 Act, and H.R. 1865, the Further consolidated Appropriations Act, 2020;
Issues related to FDA tobacco control to be considered in House and Senate in the FY20 Agriculture Appropriations legislation and CDC tobacco activities as considered in the Labor, Health and Human Services Appropriations legislation;
H.R. 293, Youth Vaping Prevention Act of 2019;
S. 616, E-Cigarette youth Protection Act;
S. 1253, Preventing Online Sales of E-Cigarettes to Children Act;
S. 1541, Tobacco-Free Youth Act;
S. 1895, Lower Health Care Costs Act regarding tobacco 21 age of sale provisions; H.R. 1865 Further Consolidated Appropriations Act, 2020 regarding tobacco 21 age of sale provisions;
S 1832, Smoke-Free Schools Act;
S. 2726, Banning Smoking on Amtrak Act of 2019;
Issues related to smoke-free policies for the Veterans Health Administration, H.R. 3700 and S. 2106;
H.R. 4249, Stop Vaping Ads Act;
S. 2550, No Tax Subsidies for E-Cigarette and Tobacco Ads Act;
H.R. 4425, Quell Underage Inhaling of Toxic Substances Act of 2019;
S. 2519, Ending New Nicotine Dependencies Act of 2019 (ENND Act);
H.R. 4624 Ending Nicotine Dependence from Electronic Nicotine Delivery Systems Act of 2019;
H.R. 5482 Providing Resources to End the Vaping Epidemic Now for Teenagers Act of 2020;
S. 3096 Providing Resources to End the Vaping Epidemic Now for Teenagers Act of 2020;
H.R. 5482 Providing Resources to End the Vaping Epidemic Now for Teenagers Act of 2020;
H.R. 5005 the Preventing Vape Use Act;
Issues related to taxation of tobacco products: S. 2463, E-cigarette Tax Parity Act; S. 2517, Tobacco Tax Equity Act of 2019, and H.R. 4742 a bill to amend the Internal Revenue Code of 1986 to impose a tax on nicotine used in e-cigarettes; and
Issues related to FDAs development of its final guidance on Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), White House Office, Federal Trade Commission (FTC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Caroline |
Powers |
|
|
|
Gregg |
Haifley |
|
|
|
Denys |
Symonette |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Rosalie |
Abbott |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Issues regarding expanding the availability of the charitable deduction for non-itemizers, issues respecting charitable giving and life income planning, issues regarding taxation of charitable organizations, and issues respecting the medical expense deduction.
Issues related to charitable IRA rollovers, including H.R. 3832 and S. 1257, the Legacy IRA Act.
Issues related to the medical expense deduction and unrelated business income taxation (UBIT) in H.R. 1865, Further Consolidated Appropriations Act, 2020.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Gregg |
Haifley |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Caroline |
Powers |
|
|
|
Rosalie |
Abbott |
|
|
|
Denys |
Symonette |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, cancer survivorship, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including:
Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019;
Issues relating to curbing health care costs;
H.R.647 & S. 2080, the Palliative Care and Hospice Education and Training Act;
Anti-cancer medication cost-sharing parity respecting H.R. 1409;
A national family caregiving strategy respecting S. 1719 and H.R. 1028;
Access to medicines respecting FDA implementation of right to try law;
Issues relating to FDA regulation of laboratory tests, Verifying Accurate Leading-edge IVCT Development Act of 2018 or the VALID Act of 2018;
H.R. 4897 & S. 2358 Women and Lung Cancer Research and Preventive Services Act of 2018;
H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for;
H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials;
Additional issues related to reducing disparities in cancer clinical trials;
Issues related to improving quality of life for cancer survivorship;
H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act;
H.Res. 14 & S.Res. 223, Expressing support for the designation of DIPG Awareness Day
H.R. 1730 and S. 741, the Cancer Drug Parity Act;
Cannabis research issues, including S. 2032 Cannabidiol and Marihuana Research Expansion Act and S. 2400Expanding Cannabis Research and Information Act ;
H.R. 2689 & S. 1438 the Breast Cancer Research Stamp Reauthorization Act
H.R. 4078 & S. 2424 EARLY Act Reauthorization of 2019
HR___, Medical Records Fairness Act (Rep. Bill Foster, D-IL);
S. 2497, the Dependent Income Exclusion Act;
SJ Res 52, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Secretary of the Treasury and the Secretary of Health and Human Services relating to "State Relief and Empowerment Waivers";
Issues related to prescription drug costs - H.R. 3, the Lower Prescription Drug Costs Now Act and S. 2543, the Prescription Drug Pricing Reduction Act of 2019;
Issues related to HHS regulation of prescription drug prices;
H.R. 4439, Creating Hope Reauthorization Act;
H.R. 1730 and S. 741, the Cancer Drug Parity Act;
S. 2546 & H.R. 2279, the Safe Step Act of 2019 - amends the Employee Retirement Income Security Act (ERISA) to require group health plans to provide an exception process for any medication step therapy protocol, tools used by health plans to control spending on patients medications, to help ensure patients are able to safely and efficiently access treatment;
S. 2911 - Seniors Prescription Drug Relief Act of 2019, would allow Medicare beneficiaries who reach an out of pocket cap to spread their payments over the course of the entire year;
Issues related to cancer survivorship and transitions of care from oncology treatment back to primary care;
S. 1608, the Promoting Physical Activity for Americans Act; and
Issues related to the nomination of Dr. Stephen Hahn to be Commissioner of the Food and Drug Administration.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Labor - Dept of (DOL), Food & Drug Administration (FDA), White House Office, State - Dept of (DOS), Natl Institutes of Health (NIH), U.S. Agency for International Development (USAID), Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Caroline |
Powers |
|
|
|
Gregg |
Haifley |
|
|
|
Denys |
Symonette |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Rosalie |
Abbott |
|
|
|
Stephanie |
Krenrich |
|
|
|
Phylicia L. |
Woods |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRA
16. Specific lobbying issues
Issues relating to requirements for ride hailing vehicles and companies, S. 1871, Samis Law.
Issues relating to highway/transportation reauthorization and appropriations.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Gregg |
Haifley |
|
|
|
Keysha |
Brooks-Coley |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |